Cat. No.
MABL-3808
Application
crystallization, in vivo, inibition, IP, therapeutic, FC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
4D5
From
Recombinant Antibody
Specificity
The original antibody is directed against the extracellular domain of p185HER2. This antibody does not cross-react with the human EGF receptor (HER1).
Alternative Names
CD340; NEU; HER-2; HER-2/neu; ERBB2; MLN 19; NGL; TKR1; erb-b2 receptor tyrosine kinase 2; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2
UniProt
P04626
Immunogen
The original antibody was generated by immunizing BALB/c mice with NIH 3T3/HER2-3400 cells expressing high levels of p185HER2.
Application Notes
The antibody immunoprecipitated p185HER2 from NIH3T3 cells. The binding of the antibody to human tumor cell lines was investigated by fluorescence-activated cell sorting. Increased in cellular fluorescence observed with SK-BR-3 breast adenocarcinoma cells and squamous carcinoma cell line A431, where the binding of the antibody correlated with the levels of p185HER2 expressed by these two cell lines. The antibody inhibited cellular proliferation of SK-BR-3 overexpressing p185HER2 by 56%. The antibody significantly affected the growth of the cell lines MDA-MB-361 and MDA-MB-175-VII, which also express high levels of p185HER2. Further, the antibody completely prevented colony formation by these cells in soft agar. Furthermore, resistance to the cytotoxic effect of tumor necrosis factor alpha is significantly reduced in the presence of this antibody (Hudziak et al., 1989; PMID: 2566907). The humanized IgG1 version of the antibody was constructed and it bound the p185HER2 antigen with higher affinity compared to its parent antibody, it had a similar potency in blocking SK-BR-3 cell proliferation and it supported antibody-dependent cellular cytotoxicity against SK-BR-3 cells (Carter et al., 1992; PMID: 1350088).
Antibody First Published
Hudziak et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor Mol Cell Biol . 1989 Mar;9(3):1165-7 PMID:2566907
Note on publication
The paper describes the generation and characterization of the antibody, which is specific for HER2.
Size
289 μg Purified antibody.
Concentration
190 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 489.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 209⁰C.
![Anti-VEGF [Bevacizumab] (MABL-](/public/static/common/images/not_adv.jpg)
